SCHEMBL8635

SCHEMBL8635

Oc1ccc(Br)cc1-c1ccccc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
HPGD P15428 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
ACMSD Q8TDX5 1/20 0.44
ALOX15 P16050 1/20 0.43
NMUR2 Q9GZQ4 1/20 0.43
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
MAPK1 P28482 1/20 0.43
IDO1 P14902 1/20 0.42
GABRA1 P14867 2/20 0.42
GABRA5 P31644 2/20 0.42
GABRA3 P34903 2/20 0.42
GABRA2 P47869 2/20 0.42
GABRB2 P47870 2/20 0.42
GABRP O00591 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29886961 1.00 MAPT (0.61) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL20321636 0.89 MEN1 (0.51) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL28591424 0.84 CA12 (0.49) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL12811627 0.84 HPGD (0.50) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL8490476 0.84 ALOX15 (0.50) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL1639158 0.82 ALOX15 (0.48) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL9108932 0.81 NMUR2 (0.48) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL20321776 0.81 HPGD (0.48) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL18338750 0.81 ACMSD (0.48) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL8743338 0.81 ALOX15 (0.62) MAPTHPGDSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US claimed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP claimed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MAPT 2989/4885HPGD 2910/4885SMN1; SMN2 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.